RxDoctor Payments Data

Mia Isadora Fronteras, MD

Endocrinology, Diabetes & Metabolism · Tampa, FLNPI 1275893158

Payments from drug & device makers

$12,613in general payments, 2019–2025

Across 665 payments — averaging $18.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Lilly USA, LLC$1K
  • Sanofi-aventis U.S. LLC$1K
  • AbbVie$898
  • Medtronic$696
  • Boehringer Ingelheim$584
  • plus $6K from 38 others

What the payments were for

  • Food & beverage$12,49999%
  • Education$550%
  • Gifts$590%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,613 in reported general payments places this provider in the 70th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.

See all endocrinology, diabetes & metabolism providers in Florida

Medicare billing

Part B allowed, 2024
$107,035
Medicare patients
227
Services billed
1,141

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide204$346,394
MounjaroTirzepatide218$316,874
SomavertPegvisomant11$256,541
JardianceEmpagliflozin97$132,242
TrulicityDulaglutide66$97,803
Soliqua 100-33Insulin Glargine/Lixisenatide37$71,631
Humulin R U-500 KwikpenInsulin Regular, Human33$68,987
RybelsusSemaglutide48$68,658
Tresiba Flextouch U-200Insulin Degludec43$60,908
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog40$50,125
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog49$48,660
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/738$48,298
FarxigaDapagliflozin Propanediol37$42,021
JanuviaSitagliptin Phosphate33$38,226
TymlosAbaloparatide13$33,426

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Fiasp$1,987$440,598265 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog$1,394$425,176317 claims
PfizerSomavert$12$256,54111 claims
Boehringer IngelheimJardiance, Synjardy Xr, Synjardy$584$174,975134 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$1,266$71,63137 claims
MerckJanuvia, Janumet$209$61,73758 claims
AstraZenecaFarxiga$161$42,02137 claims
Radius Health, Inc.Tymlos$172$33,42613 claims
AbbVieSynthroid$898$12,656127 claims
Johnson & JohnsonInvokana$87$9,45113 claims
IBSA Pharma Inc.Tirosint, Tirosint-Sol$239$7,45627 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$237$4,870310 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.

Other endocrinology, diabetes & metabolism in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →